Voyager Therapeutics Announces Third Quarter 2022 Conference Call and Webcast
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Voyager Therapeutics, Inc. (Nasdaq: VYGR) announced it will disclose its third-quarter 2022 financial and operational results before the market opens on November 8, 2022. Following the results, a live conference call and webcast will occur at 8:30 a.m. ET to discuss the findings. Interested participants can register for the call to receive dial-in details and access a live webcast on Voyager's investor website. Voyager is focused on next-generation AAV gene therapy, aiming to treat debilitating diseases using its proprietary capsids from the TRACER™ discovery platform.
Positive
- Focus on next-generation AAV gene therapy, indicating potential for innovative treatments.
- Proprietary TRACER™ capsid discovery platform may enhance the effectiveness of therapies.
Negative
- None.
Details
News Market Reaction – VYGR
The recorded move for VYGR in the trading session of this news was +1.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced it will report third quarter 2022 financial and operating results before the market opens on Tuesday, November 8, 2022. Subsequently, the Company will host a live conference call and webcast at 8:30 a.m. ET to review its financial and operating results.
To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BIa813418ea1c148dda525a8560a51e1ca. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from Voyager’s TRACER™ capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com LinkedIn Twitter
Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.